-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Yifan Pharmaceutical's announcement, Yifan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration on June 24, 2025, and agreed to carry out clinical trials of biosimilar drugs for insulin glargine injections. This product is a biosimilar. The original product was Sanofi's LaideTime®. The indications in this application are consistent with those currently approved by Laidex® in China. It is type 1 and type 2 diabetes in adults requiring insulin treatment, and type 1 diabetes in adolescents and children aged 6 and above.

Zhitongcaijing·06/25/2025 10:41:16
Listen to the news
According to Yifan Pharmaceutical's announcement, Yifan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration on June 24, 2025, and agreed to carry out clinical trials of biosimilar drugs for insulin glargine injections. This product is a biosimilar. The original product was Sanofi's LaideTime®. The indications in this application are consistent with those currently approved by Laidex® in China. It is type 1 and type 2 diabetes in adults requiring insulin treatment, and type 1 diabetes in adolescents and children aged 6 and above.